(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each Class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Exhibit Number | Description of Document | |||||||
99.1 | ||||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIO GENE THERAPIES INC. | |||||||||||||||||
Dated: | February 14, 2023 | ||||||||||||||||
By: | /s/ David Nassif | ||||||||||||||||
Name: | David Nassif | ||||||||||||||||
Title: | Chief Executive Officer; Chief Financial Officer; Chief Accounting Officer; and General Counsel |
Three Months Ended December 31, | Nine Months Ended December 31, | ||||||||||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||
Research and development expenses | |||||||||||||||||||||||
(includes stock-based compensation expense (benefit) of $0 and $130 for the three months ended December 31, 2022 and 2021 and $(409) and $1,051 for the nine months ended December 31, 2022 and 2021, respectively) | $ | 1,883 | $ | 21,287 | $ | 7,761 | $ | 40,793 | |||||||||||||||
General and administrative expenses | |||||||||||||||||||||||
(includes stock-based compensation expense of $227 and $1,268 for the three months ended December 31, 2022 and 2021 and $692 and $8,966 for the nine months ended December 31, 2022 and 2021, respectively) | 2,600 | 4,086 | 8,533 | 17,693 | |||||||||||||||||||
Total operating expenses | 4,483 | 25,373 | 16,294 | 58,486 | |||||||||||||||||||
Other (income) expenses: | |||||||||||||||||||||||
Other (income) expense, net | (464) | 83 | (785) | 105 | |||||||||||||||||||
Loss before income tax benefit | (4,019) | (25,456) | (15,509) | (58,591) | |||||||||||||||||||
Income tax benefit | — | — | (4) | (28) | |||||||||||||||||||
Net loss | $ | (4,019) | $ | (25,456) | $ | (15,505) | $ | (58,563) | |||||||||||||||
Net loss per share of common stock — basic and diluted | $ | (0.05) | $ | (0.35) | $ | (0.21) | $ | (0.80) | |||||||||||||||
Weighted-average shares of common stock outstanding — basic and diluted | 73,975,196 | 73,335,279 | 73,905,737 | 73,046,889 |
December 31, 2022 | March 31, 2022 | ||||||||||
Assets | |||||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 46,127 | $ | 63,729 | |||||||
Restricted cash | — | 1,184 | |||||||||
Prepaid expenses and other current assets | 789 | 5,214 | |||||||||
Income tax receivable | 356 | 1,609 | |||||||||
Total current assets | 47,272 | 71,736 | |||||||||
Operating lease right-of-use assets | — | 2,444 | |||||||||
Property and equipment, net | — | 900 | |||||||||
Total assets | $ | 47,272 | $ | 75,080 | |||||||
Liabilities and Stockholders’ Equity | |||||||||||
Current liabilities: | |||||||||||
Accounts payable | $ | 201 | $ | 3,984 | |||||||
Accrued expenses | 1,951 | 8,232 | |||||||||
Current portion of operating lease liabilities | — | 786 | |||||||||
Total current liabilities | 2,152 | 13,002 | |||||||||
Operating lease liabilities, net of current portion | — | 1,730 | |||||||||
Total liabilities | 2,152 | 14,732 | |||||||||
Stockholders’ equity: | |||||||||||
Common stock, par value $0.00001 per share, 1,000,000,000 shares authorized, 73,975,196 and 73,739,378 issued and outstanding at December 31, 2022 and March 31, 2022, respectively | 1 | 1 | |||||||||
Additional paid-in capital | 923,249 | 922,966 | |||||||||
Accumulated deficit | (878,461) | (862,956) | |||||||||
Accumulated other comprehensive income | 331 | 337 | |||||||||
Total stockholders’ equity | 45,120 | 60,348 | |||||||||
Total liabilities and stockholders’ equity | $ | 47,272 | $ | 75,080 |
Nine Months Ended December 31, | |||||||||||
2022 | 2021 | ||||||||||
Cash flows from operating activities: | |||||||||||
Net loss | $ | (15,505) | $ | (58,563) | |||||||
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||||
Non-cash lease expenses | 2,444 | 229 | |||||||||
Stock-based compensation expense | 283 | 10,017 | |||||||||
Depreciation and non-cash amortization | 137 | 187 | |||||||||
Change in operating lease liabilities | (2,516) | (265) | |||||||||
Other | 857 | 7 | |||||||||
Changes in operating assets and liabilities: | |||||||||||
Prepaid expenses and other current assets | 4,425 | 2,104 | |||||||||
Income tax receivable | 1,253 | (76) | |||||||||
Accounts payable | (3,783) | 5,270 | |||||||||
Accrued expenses | (6,281) | (1,434) | |||||||||
Net cash used in operating activities | (18,686) | (42,524) | |||||||||
Cash flows from investing activities: | |||||||||||
Cash proceeds from sale of long-term investment | — | 4,343 | |||||||||
Cash proceeds from sale of property and equipment | 190 | — | |||||||||
Purchases of property and equipment | (290) | (336) | |||||||||
Net cash (used in) provided by investing activities | (100) | 4,007 | |||||||||
Cash flows from financing activities: | |||||||||||
Cash proceeds from issuance of shares of common stock, net of issuance costs | — | 1,441 | |||||||||
Net cash provided by financing activities | — | 1,441 | |||||||||
Net change in cash and cash equivalents, restricted cash and long-term restricted cash | (18,786) | (37,076) | |||||||||
Total cash and cash equivalents, restricted cash and long-term restricted cash—beginning of period | 64,913 | 120,170 | |||||||||
Total cash and cash equivalents, restricted cash and long-term restricted cash—end of period | $ | 46,127 | $ | 83,094 | |||||||
Cash and cash equivalents —beginning of period | 63,729 | 118,986 | |||||||||
Restricted cash included in current assets—beginning of period | 1,184 | — | |||||||||
Restricted cash included in long-term assets—beginning of period | — | 1,184 | |||||||||
Total cash and cash equivalents, restricted cash and long-term restricted cash—beginning of period | $ | 64,913 | $ | 120,170 | |||||||
Cash and cash equivalents—end of period | 46,127 | 81,910 | |||||||||
Restricted cash included in current assets—end of period | — | 1,184 | |||||||||
Total cash and cash equivalents and restricted cash—end of period | $ | 46,127 | $ | 83,094 | |||||||
.+.3>8[N^;4HI'7:&6?][\O
MJ 6*Y_V37VQ_P33^)"^)/@[J/A2>93=^'+UO*C5-NVVF)=23_$?,\[Z#%<6,
MP=&&&C7HK>QUX3%595W1JO8^P****^?/<"BBB@ HHHH **** /S@_P""G?PW
MM-&\9^&/&5G;F.76()+._9$ 1I(MIC=CU+,K%>>T8KC?^"VCC1OD\U,2AF'?"HX'^]7NW_ 5'U:VA^'O@W368?:[C4WGC7N42
M,AC^;K7S5^P'H]UJ7[47AFXMXC)%8075Q<-_/\ MF,YKQ_QY_P4,^+?C#SX=.N=/\*6
Cover Page |
Feb. 14, 2023 |
---|---|
Entity Addresses [Line Items] | |
Document Type | 8-K |
Document Period End Date | Feb. 14, 2023 |
Entity Registrant Name | Sio Gene Therapies Inc. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-37418 |
Entity Tax Identification Number | 85-3863315 |
Entity Address, Address Line One | 1501 Broadway |
Entity Address, Address Line Two | 12th Floor |
Entity Address, City or Town | New York |
Entity Address, State or Province | NY |
Entity Address, Postal Zip Code | 10036 |
Country Region | 1 |
City Area Code | 646 |
Local Phone Number | 677 6770 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.00001 per share |
Trading Symbol | SIOX |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Amendment Flag | false |
Entity Central Index Key | 0001636050 |
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end
^*3#!SL_8S+"GJ4EJ(\'>C044V'GIME31*IE' YI<5E.]=>/U
M*O6R&]J>;7IQ23:ELB'5&LDW%%V-"!F"%OGB:D65JFH"8[,3KN8HL[[:4D'3
M?F3>SI8*%LGV+=!R:VEX54FY'^7"/'(=H)01RK-'+89[4%B._5#RF1M).*Y@
M.;"X>[US'XOH>^?3)EHE:9(TI=%WE@T&_ H@W'_ALWFX_>AH;9.1W0!0:>[Q
M!-(B1L_$:;X'A3!N E4)SDWZR)R*Z[.E:;#1QDZO>R\*@^CU((E^)'T5.8$"29A2R@CQRQ=**),MK+OE+63IOL4%,
M@R%:+9W7-VUJZYM*YR5-N>8UG;